Our work is to really get to the bottom of these mechanisms. To identify step-by-step the sequences that lead to the disease and to the treatment that can be given.
In itself, the virtual population, irrespective of its important role in the use of models, has other qualities. The first quality is to be able to collect data that are today stored in various dispersed databases…
Clearly the model enables us to learn more about the mechanism of action of the therapy and this is unprecedented compared with «small aspects» that we were concerned about through in vitro and in vivo trials.
In reality, we face two problems when we develop our models. The first one is that we are in the limit of knowledge.
We have several teams: biostatisticians, mathematical developers… I am more in the field of bio-modeling that straddles mathematics and biology.